<DOC>
	<DOCNO>NCT01618448</DOCNO>
	<brief_summary>A Multicenter , Double-blind , Randomized , Placebo-Controlled Study Evaluate Efficacy Safety Tolvaptan Treatment Cardiac-Induced Edema Patients Heart Failure</brief_summary>
	<brief_title>Efficacy Safety Tolvaptan Treatment Cardiac-Induced Edema Patients With Heart Failure</brief_title>
	<detailed_description>Interventional , phase III , 2-arm parallel group , placebo-controlled , multicenter , randomize 1:1 , double-blind study , compare Tolvaptan placebo hospitalize HF patient sign symptom congestion time randomization spite standard therapy.This study intend demonstrate repeat 4-day treatment Tolvaptan addition standard care ( SOC ) superior SOC alone treatment clinical relevant cardiac-induced volume retention parameter patient hospitalize worsen HF initially treat conventional therapy include diuretic .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Edema , Cardiac</mesh_term>
	<mesh_term>Tolvaptan</mesh_term>
	<criteria>2 . Patients history chronic HF hospitalize primarily worsen HF sign symptom volume congestion spite standard therapy 3 . Patient HF symptom rest minimal exertion sign congestion ( low limb edema , jugular venous distention , pulmonary congestion due extracellular volume expansion ) time randomization c. Antialdosterone drug : Spironolactone , Triamterene 4 . Patients undergo follow diuretic therapy : A loop diuretic daily dosage equivalent 40 mg furosemide Concomitant administration loop diuretic thiazide diuretic ( dos ) Concomitant administration loop diuretic antialdosterone drug ( dos ) Note : The allowable type dosages concomitantly administer diuretic specify follow : 1 . Loop diuretic equivalent 40 mg furosemide : Bumetanide : 1 mg , Piretanide : 6 mg , Azosemide : 60 mg , Torasemide : 8 mg 2 . Thiazide diuretic : Hydrochlorothiazide , Trichloromethiazide , Benzyl hydrochlorothiazide , Chlortalidone , Mefruside 5 . Patients take orally administer diuretic without change dose mode administration Observation period 6 . Patients whose body weight variation within 1.0 kg 2 day prior start treatment 7 . Patients able accomplish study procedure Screening period Poststudy followup 8 . Patients capable give informed consent participate study free . 1 . Cardiac surgery within 60 day enrollment 2 . Patients assist cardiac mechanical device 3 . Patients receive CRT ( Cardiac Resynchronization Therapy ) within 60 day enrollment . 4 . Patients active significant complication symptom follow : Suspected decrease circulatory blood flow Refractory endstage HF ( patient consider require mechanical circulatory support , continuous intravenous positive inotropic therapy , referral cardiac transplantation , hospice care ) Cardiac valvular disease significant heart valve stenosis Sustained ventricular tachycardia ventricular fibrillation within 30 day prior screen examination Acute myocardial infarction within 30 day prior screen examination Cerebrovascular disorder within 6 month prior screen examination ( asymptomatic cerebral infarction ) Patients definite diagnosis active myocarditis amyloid cardiomyopathy Poorly control Diabetes Mellitus ( HbAlc 10 % ) Anuria ( urinary output le 100 ml per day ) History Hyperthyroidism Urination impair due urinary tract stricture , urinary calculus , tumor urinary tract , cause Hemofiltration dialysis Patients unable sense thirst , inappropriately respond thirst impaired oral fluid intake . 5 . Patients history hypersensitivity idiosyncratic reaction benzazepine derivative mozavaptan hydrochloride benazepril hydrochloride 6 . Patients severely obese ( BMI exceed 35 kg/m2 ) 7 . Patients systolic blood pressure decubitus position 90 mmHg 8 . Patients follow abnormal laboratory value : Total bilirubin exceed 3.0 mg/dL , hemoglobin le 9 g/dL , serum creatinine exceed 3.0 mg/dL , serum sodium exceed 147 mEq/L , serum potassium exceed 5.5 mEq/L 9 . Female patient pregnant , possibly pregnant , lactate , plan become pregnant 10 . Patients receive investigational drug Tolvaptan within 30 day prior screen examination 11 . Patients general physical condition , may confound result study , pose additional risk preclude evaluation assessment study</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>